Response to commentary: Head-to-head trial of pegunigalsidase alfa versus agalsidase beta in patients with Fabry disease and deteriorating renal function: results from the 2-year randomised phase III BALANCE study - determination of immunogenicity.
J Med Genet
; 61(6): 534-535, 2024 May 21.
Article
de En
| MEDLINE
| ID: mdl-38589225
Texte intégral:
1
Collection:
01-internacional
Base de données:
MEDLINE
Sujet principal:
Protéines recombinantes
/
Maladie de Fabry
/
Alpha-Galactosidase
/
Isoenzymes
Limites:
Humans
Langue:
En
Journal:
J Med Genet
Année:
2024
Type de document:
Article
Pays d'affiliation:
États-Unis d'Amérique